Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Prognostic relevance of mutational profile in secondary Acute Myeloid Leukemia patients treated with CPX-351.

View Full Paper
Ask AI
Bookmark
Share

Authors

SNStefano NicolettaECEnrico CarminatiFPFrancesco Puglisi

Discussion

Loading...

Member takes

Overview

Observational analysis shows minimal residual disease rates in secondary Acute Myeloid Leukemia patients treated with CPX-351, suggesting potential mutation-related outcomes.

Key Points

  • Survival improved for patients with MPN-like mutations or splicing mutations in the absence of TP53.
  • Analysis of bone marrow samples revealed significant mutation patterns associated with treatment response or failure.
  • Mutations in DNA methylation genes correlated with longer survival, while cohesion gene mutations indicated poorer outcomes.
  • Minimal residual disease analysis highlighted a substantial rate of complete remission among treated patients.

Cite This Study

Nicoletta et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e453https://doi.org/10.1182/blood-2025-1623
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Molecular profile linked to resistance to hypomethilating agents plus venetoclax does not predict outcome in secondary Acute Myeloid Leukemia patients receiving CPX-351 induction.2025
  2. 2CPX-351 is effective in secondary Acute Myeloid Leukemia, regardless if defined according to 2016 or 2022 edition of who classification.2025
  3. 3Molecular response of Acute Myeloid Leukemia to induction with CPX-351 and its impact on prognosis2025
  4. 4Real‐world analysis of <scp>CPX</scp> ‐351 in <scp>AML</scp> ‐ <scp>MR</scp> : A multicentre study from the <scp>MARROW</scp> consortium2025 · 1 citations
  5. 5CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with  myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study2025